ReviewDigestive diseases and sciences2017
Gastroparesis: Medical and Therapeutic Advances.
Review in Digestive diseases and sciences, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 52 citations in OpenAlex.
- Clinical insights into diabetic gastroparesis: gastric scintigraphy-based diagnosis and treatment outcomes.BMC gastroenterology · 2025Article
- Gastric electrical stimulation versus standard medical therapies for long-term symptom control and improved quality of life in drug-refractory gastroparesis patients.Annals of medicine and surgery (2012) · 2025Review
- Significant changes in impedance planimetry (EndoFLIP™) measurements after peroral pyloromyotomy for delayed gastric emptying.Surgical endoscopy · 2022Article
- A Systematic Review of the Therapeutic Role of Gastric Pacemakers in Adults With Gastroparesis.Cureus · 2021Review
- Gastric Emptying Scans: Poor Adherence to National Guidelines.Digestive diseases and sciences · 2021Article
- A Low Cost, Novel Treatment of Severe Diabetic Gastroparesis Based on Burkitt's Dietary Fiber Hypothesis.Cureus · 2021Article
- Gastroparesis and Severity of Delayed Gastric Emptying: Comparison of Patient Characteristics, Treatments and Medication Adverse Events.Digestive diseases and sciences · 2021Article
- Toward an Improved Treatment for Gastroparesis.Journal of neurogastroenterology and motility · 2020Article
- Minimally Invasive Gastric Electrical Stimulation Using a Newly Developed Wireless Gastrostimulator: A Pilot Animal Study.Journal of neurogastroenterology and motility · 2020Article
- Gastroparesis in the 2020s: New Treatments, New Paradigms.Current gastroenterology reports · 2020Review
- A Novel Approach in Spinal Cord Stimulation for Enhancing Gastric Motility: A Preliminary Study on Canines.Journal of neurogastroenterology and motility · 2020Article
- Preoperative Blood Glucose Level Predicts Postsurgical Gastroparesis Syndrome after Subtotal Gastrectomy: Development of an Individualized Usable Nomogram.Journal of diabetes research · 2020Article
- Vagus Nerve Stimulation at the Interface of Brain-Gut Interactions.Cold Spring Harbor perspectives in medicine · 2019Review
- Prokinetic effects of spinal cord stimulation and its autonomic mechanisms in dogs.Neurogastroenterology and motility · 2019Article
- Efficacy and feasibility of G-POEM in management of patients with refractory gastroparesis: a systematic review and meta-analysis.Endoscopy international open · 2019Review
- Therapeutic effect of a temporary transpyloric stent in refractory post-surgical gastroparesis: a case report.BMC surgery · 2019Article
- Gastroparesis and Functional Dyspepsia: A Blurring Distinction of Pathophysiology and Treatment.Journal of neurogastroenterology and motility · 2019Review
- Diabetic Gastroparesis: Principles and Current Trends in Management.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2018Review
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastroparesis is a chronic, bothersome, and often disabling neuromuscular disorder of the upper gastrointestinal tract. The most frequently reported symptoms of gastroparesis include nausea, vomiting, epigastric pain, early satiety, and unintentional weight loss. Etiologies of gastroparesis include diabetes, connective tissue disorders, prior infection, mesenteric ischemia, and post-surgical complications. The largest category of gastroparesis patients is comprised of those in whom no definitive cause can be identified (idiopathic gastroparesis). The individual and societal burden of gastroparesis is substantial. It considerably reduces patients' quality of life accompanied by a significant negative impact to the healthcare system. The current treatments of gastroparesis are less than ideal. Dietary modification may improve symptoms in patients with mild disease. Metoclopramide is the only medication currently approved for the treatment of gastroparesis; however, it is associated with adverse effects in a sizable proportion of patients. Other medications are frequently employed to treat symptoms of nausea and vomiting, although technically all are used off-label since they are not FDA approved for the treatment of gastroparesis. These data highlight the need to identify novel, more effective treatment options for this disabling disease. This review will provide a brief synopsis on the epidemiology, etiology, and impact of gastroparesis, discussing new therapeutic advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.